<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Orion Oyj A — News on 6ix</title>
<link>https://6ix.com/company/orion-oyj-a</link>
<description>Latest news and press releases for Orion Oyj A on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/orion-oyj-a" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683620ba78dffbe2df141566.webp</url>
<title>Orion Oyj A</title>
<link>https://6ix.com/company/orion-oyj-a</link>
</image>
<item>
<title>Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-pharma-initiates-teadco-phase-1b2-basket-trial-evaluating-odm-212-in-combination-with-standard-of-care-treatments-in-patients-with-select-advanced-solid-tumours</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-pharma-initiates-teadco-phase-1b2-basket-trial-evaluating-odm-212-in-combination-with-standard-of-care-treatments-in-patients-with-select-advanced-solid-tumours</guid>
<pubDate>Thu, 23 Apr 2026 06:00:00 GMT</pubDate>
<description>ORION CORPORATION PRESS RELEASE 23 APRIL 2026 at 09.00 EEST Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours Orion Corporation (Orion Pharma) today announced the initiation of a Phase 1b/2 basket trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, in combination with standard of care treatments in advanced mesothelioma, KRAS G12C mutated non-small cell</description>
</item>
<item>
<title>Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-corporation-transfer-of-172778-own-b-shares-on-10-march-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-corporation-transfer-of-172778-own-b-shares-on-10-march-2026-5</guid>
<pubDate>Tue, 10 Mar 2026 11:50:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES10 MARCH 2026 at 13.50 EET Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2026 transferred altogether 172,778 Orion Corporation B shares held by the company as a share reward for earning period 2023–2025 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. T</description>
</item>
<item>
<title>Orion Group Financial Statement documents 2025 and Remuneration Report published</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-group-financial-statement-documents-2025-and-remuneration-report-published-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-group-financial-statement-documents-2025-and-remuneration-report-published-1</guid>
<pubDate>Fri, 27 Feb 2026 09:05:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET Orion Group Financial Statement documents 2025 and Remuneration Report published Orion Group's Financial Statement documents for 2025 have been published. The documents are available in Finnish and English on the Company's website at https://www.orionpharma.com and are attached to this release. Financial Statement documents include the company’s Financial Statements, the Report by the Board of Direct</description>
</item>
<item>
<title>The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons</title>
<link>https://6ix.com/company/orion-oyj-a/news/the-board-of-directors-of-orion-corporation-decided-on-a-new-plan-period-for-the-long-term-incentive-program-for-the-companys-key-persons-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/the-board-of-directors-of-orion-corporation-decided-on-a-new-plan-period-for-the-long-term-incentive-program-for-the-companys-key-persons-1</guid>
<pubDate>Thu, 12 Feb 2026 11:12:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE12 FEBRUARY 2026 at 13.12 EET The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons The Board of Directors of Orion Corporation decided on a new Long-term Incentive Program on February 25, 2025. The Long-term Incentive Program consists of annually launched performance share plans, offering participants th</description>
</item>
<item>
<title>Notice to the Annual General Meeting of Orion Corporation</title>
<link>https://6ix.com/company/orion-oyj-a/news/notice-to-the-annual-general-meeting-of-orion-corporation-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/notice-to-the-annual-general-meeting-of-orion-corporation-1</guid>
<pubDate>Thu, 12 Feb 2026 10:05:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 12 FEBRUARY 2026 at 12:05 EET Notice to the Annual General Meeting of Orion Corporation Notice is given to the shareholders of Orion Corporation of the Annual General Meeting to be held on Tuesday 24 March 2026 at 2:00 p.m. Finnish time at Messukeskus Siipi conference centre at the address Rautatieläisenkatu 3, Helsinki, Finland. The reception of attendees who have registered for the meeting and the distribution of voting ticke</description>
</item>
<item>
<title>Orion Group Financial Statement Release January–December 2025</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-group-financial-statement-release-january-december-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-group-financial-statement-release-january-december-2025-1</guid>
<pubDate>Thu, 12 Feb 2026 10:00:00 GMT</pubDate>
<description>ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October–December 2024: 434.4) million Operating profit was EUR 328.1 (92.7) millionBasic earnings per share were EUR 1.85 (0.52)Cash flow from operating activities per share was EUR 0.58 (0.63)The outlook for 2026 (provided on 14 January 2026): Net sales are estimated to be EUR 1,900 mill</description>
</item>
<item>
<title>62,752 Orion Corporation A shares converted into B shares</title>
<link>https://6ix.com/company/orion-oyj-a/news/62752-orion-corporation-a-shares-converted-into-b-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/62752-orion-corporation-a-shares-converted-into-b-shares-1</guid>
<pubDate>Tue, 03 Feb 2026 07:00:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 3 FEBRUARY 2026 at 9.00 EET 62,752 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 62,752 A shares have been converted into 62,752 B shares. The conversion has been entered into the Trade Register on 3 February 2026. The total number of shares in Orion Corporation is 141,134,278 which, after the conversi</description>
</item>
<item>
<title>Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-publishes-financial-statement-release-for-2025-and-holds-a-webcast-on-12-february-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-publishes-financial-statement-release-for-2025-and-holds-a-webcast-on-12-february-2026-1</guid>
<pubDate>Fri, 30 Jan 2026 07:30:00 GMT</pubDate>
<description>ORION CORPORATION PRESS RELEASE 30 JANUARY 2026 at 9.30 EET Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026 Orion will publish Financial Statement Release for 2025 on Thursday, 12 February 2026 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orionpharma.com/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and</description>
</item>
<item>
<title>Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-corporation-disclosure-under-chapter-9-section-10-of-the-securities-market-act-blackrock-inc-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-corporation-disclosure-under-chapter-9-section-10-of-the-securities-market-act-blackrock-inc-1</guid>
<pubDate>Tue, 20 Jan 2026 06:30:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through</description>
</item>
<item>
<title>182,827 Orion Corporation A shares converted into B shares</title>
<link>https://6ix.com/company/orion-oyj-a/news/182827-orion-corporation-a-shares-converted-into-b-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/182827-orion-corporation-a-shares-converted-into-b-shares-1</guid>
<pubDate>Fri, 16 Jan 2026 07:30:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 16 JANUARY 2026 at 9:30 EET 182,827 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 182,827 A shares have been converted into 182,827 B shares. The conversion has been entered into the Trade Register on 16 January 2026. The total number of shares in Orion Corporation is 141,134,278 which, after the conve</description>
</item>
<item>
<title>Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting</title>
<link>https://6ix.com/company/orion-oyj-a/news/recommendation-by-the-orion-nomination-committee-on-the-proposals-to-be-presented-to-the-2026-annual-general-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/recommendation-by-the-orion-nomination-committee-on-the-proposals-to-be-presented-to-the-2026-annual-general-meeting-1</guid>
<pubDate>Thu, 15 Jan 2026 14:30:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE15 JANUARY 2026 at 16:30 EET Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting The Nomination Committee of Orion Corporation has on 15 January 2026 given to the company’s Board of Directors its recommendation on the proposal to the Annual General Meeting of 2026 concerning the composition of the Board of Directors to be el</description>
</item>
<item>
<title>Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-updates-time-estimate-for-the-potential-related-to-the-annual-nubeqar-net-sales-recorded-by-orion-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-updates-time-estimate-for-the-potential-related-to-the-annual-nubeqar-net-sales-recorded-by-orion-1</guid>
<pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE 14 JANUARY 2026 at 16:00 EET Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion As the company announced earlier today on 14 January 2026, the Nubeqa® product has become Orion's largest product by far, and its financial significance for the company will increase further. For this reason, Orion decided to provide an estimate of the net sales potential of Nubeqa®. As noted earlier, based on scenario plann</description>
</item>
<item>
<title>Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future</title>
<link>https://6ix.com/company/orion-oyj-a/news/inside-information-orion-provides-outlook-for-2026-and-estimates-that-the-annual-nubeqar-net-sales-recorded-by-orion-has-potential-to-exceed-eur-1-billion-in-the-future-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/inside-information-orion-provides-outlook-for-2026-and-estimates-that-the-annual-nubeqar-net-sales-recorded-by-orion-has-potential-to-exceed-eur-1-billion-in-the-future-1</guid>
<pubDate>Wed, 14 Jan 2026 06:30:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 14 JANUARY 2026 at 8:30 EET Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future The Nubeqa® product has become Orion's largest product by far, and its financial significance for the company will increase further. For this reason, Orion has decided to provide an estimate of the net sales potential of Nubeqa®. Based on s</description>
</item>
<item>
<title>Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-pharma-announces-the-initiation-of-teades-phase-2-trial-of-odm-212-in-malignant-pleural-mesothelioma-mpm-and-epithelioid-hemangioendothelioma-ehe-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-pharma-announces-the-initiation-of-teades-phase-2-trial-of-odm-212-in-malignant-pleural-mesothelioma-mpm-and-epithelioid-hemangioendothelioma-ehe-1</guid>
<pubDate>Thu, 08 Jan 2026 10:00:00 GMT</pubDate>
<description>ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) Orion Corporation (Orion Pharma) announces initiation of a Phase 2 trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, as a monotherapy in malignant pleural mesothelioma (MPM) and epithelioid hemangioendothelioma (EHE), which are rare and difficult to treat</description>
</item>
<item>
<title>Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025</title>
<link>https://6ix.com/company/orion-oyj-a/news/inside-information-orion-to-receive-eur-180-million-milestone-and-updates-full-year-outlook-for-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/inside-information-orion-to-receive-eur-180-million-milestone-and-updates-full-year-outlook-for-2025-1</guid>
<pubDate>Wed, 03 Dec 2025 07:00:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 3 DECEMBER 2025 at 09.00 EET Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025 Orion Corporation has been informed that it will receive a milestone payment of EUR 180 million related to sales of Nubeqa®, which will be recorded in the fourth quarter of 2025. Due to receiving the milestone, Orion updates the full-year outlook for 2025 in terms of both net sales and operating profit. Ne</description>
</item>
<item>
<title>71,498 Orion Corporation A shares converted into B shares</title>
<link>https://6ix.com/company/orion-oyj-a/news/71498-orion-corporation-a-shares-converted-into-b-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/71498-orion-corporation-a-shares-converted-into-b-shares-1</guid>
<pubDate>Thu, 27 Nov 2025 07:00:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2025 at 9.00 EET 71,498 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 71,498 A shares have been converted into 71,498 B shares. The conversion has been entered into the Trade Register on 27 November 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conver</description>
</item>
<item>
<title>Orion receives award for international growth from the President of the Republic of Finland</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-receives-award-for-international-growth-from-the-president-of-the-republic-of-finland-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-receives-award-for-international-growth-from-the-president-of-the-republic-of-finland-1</guid>
<pubDate>Fri, 14 Nov 2025 11:30:00 GMT</pubDate>
<description>ORION CORPORATION PRESS RELEASE 14 NOVEMBER 2025 at 13.30 EET Orion receives award for international growth from the President of the Republic of Finland Today, the President of the Republic of Finland, Alexander Stubb, has awarded Orion Corporation the Internationalisation Award of the President in the growth companies category. The Internationalisation Awards of the President of the Republic of Finland are bestowed annually in recognition of internationally successful Finnish companies or comm</description>
</item>
<item>
<title>Orion Group Interim Report January–September 2025</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-group-interim-report-january-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-group-interim-report-january-september-2025-1</guid>
<pubDate>Tue, 28 Oct 2025 10:00:00 GMT</pubDate>
<description>ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 Highlights Net sales totalled EUR 423.2 (July–September 2024: 471.3) million Operating profit was EUR 121.0 (202.0) millionNet sales and operating profit of the comparison period include EUR 130 million of major milestone paymentsBasic earnings per share were EUR 0.68 (1.14)Cash flow from operating activities per share was EUR 0.55 (0.48)The outlook for 202</description>
</item>
<item>
<title>49,164 Orion Corporation A shares converted into B shares</title>
<link>https://6ix.com/company/orion-oyj-a/news/49164-orion-corporation-a-shares-converted-into-b-shares-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/49164-orion-corporation-a-shares-converted-into-b-shares-1</guid>
<pubDate>Fri, 24 Oct 2025 06:00:00 GMT</pubDate>
<description>ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 OCTOBER 2025 at 9.00 EEST 49,164 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 49,164 A shares have been converted into 49,164 B shares. The conversion has been entered into the Trade Register on 24 October 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the convers</description>
</item>
<item>
<title>Orion and Abzena announce exclusive commercial license for Abzena’s antibody</title>
<link>https://6ix.com/company/orion-oyj-a/news/orion-and-abzena-announce-exclusive-commercial-license-for-abzenas-antibody-1</link>
<guid isPermaLink="true">https://6ix.com/company/orion-oyj-a/news/orion-and-abzena-announce-exclusive-commercial-license-for-abzenas-antibody-1</guid>
<pubDate>Thu, 23 Oct 2025 12:30:00 GMT</pubDate>
<description>ORION CORPORATION PRESS RELEASE 23 OCTOBER 2025 at 15:30 EEST Orion and Abzena announce exclusive commercial license for Abzena’s antibody Orion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad oncology-focused d</description>
</item>
</channel>
</rss>